Evaluation of capnographic differences in COPD patients with and without hypercapnia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034154

Enrollment

Registered

2024-04-24

Start date

2024-06-06

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J44

Interventions

Group 1: Patients diagnosed with severe stage COPD (GOLD stages 3 and 4) with and without hypercapnia.

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Ability to consent 2. Written informed consent 3. Patients with severe stage COPD (GOLD stage 3 and 4) 4. Patients without hypocapnia (patients with paCO2>35mmHg) 5. Patients must be able to sit upright for several minutes without fatigue 6. Patients must be able to go 10 minutes without supplemental oxygen (as assessed by the investigator).

Exclusion criteria

Exclusion criteria: 1. Patients who, in the opinion of the investigator, are unsuitable for participation in this study or cannot fulfil the requirements of the study. 2. Currently participating in a clinical trial that could influence respiratory behaviour (drug, medical device) or within the last 30 days prior to the study. This is at the discretion of the investigator. 3. Participation in this study at an earlier date. 4. Patients with previously documented heart failure with an ejection fraction below 45% or acute hydropic decompensation. 5. Patients with documented neuromuscular and diaphragmatic restrictions. 6. Patients with mouth closure problems. 7. Patients with a respiratory rate > 22 breaths per minute at rest. 8. Acute pulmonary exacerbation with inflammatory activity or acute pulmonary infection within 4 weeks prior to screening. 9. Patients who are potentially or manifestly pregnant. 10. Hypersensitivity to the ingredients of the hyperaemising ointment (Finalgon).

Design outcomes

Primary

Measure	Time frame
1. Evaluation of the differences in pCO2 from capillary BGA and petCO2 from different breathing manoeuvres in COPD patients with and without hypercapnia. 2. Evaluation of the changes in petCO2 during different breathing manoeuvres in COPD patients with and without hypercapnia.	—

Secondary

Measure	Time frame
1. Evaluation of the applicability/feasibility of the lumetry research device. 2. Comparison of pCO2 and petCO2 with transcutaneous CO2 (tCO2) measurements at rest.	—

Countries

Germany

Contacts

Public ContactMavi Schellenberg

Thoraxklinik Heidelberg gGmbH

mavi.schellenberg@med.uni-heidelberg.de+49 6221 396 8027

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026